How Biogen Makes Money

Biogen discovers, licenses or acquires drug candidates, runs the clinical trials needed for approval, manufactures most of its biologics in Research Triangle Park, North Carolina and Solothurn, Switzerland, and sells approved products through specialty pharmacies, hospitals and infusion centers. Revenue comes from three places: product sales (about 70% of Q2 2026 revenue, led by Tysabri, Spinraza, Vumerity, Skyclarys, Syfovre and Zurzuvae), royalties and profit share on Genentech's anti-CD20 drugs such as Ocrevus ($514 million in Q2 2026), and its share of Leqembi economics with Eisai plus contract manufacturing. Prices are high because the diseases are severe and patient groups small: Spinraza launched at about $750,000 for the first year of treatment. Many assets are partnered, so Biogen shares costs and profits with Eisai, Ionis, UCB, Supernus and others.

Viehbacher's plan has three parts. First, cut costs: the Fit for Growth program launched in 2023 targeted about $1 billion of gross savings and removed roughly 1,000 roles. Second, launch newer drugs such as Leqembi, Skyclarys, Zurzuvae and Qalsody; the growth portfolio reached $1.1 billion of revenue in Q2 2026, up 24%. Third, buy late-stage or commercial assets beyond core neurology: Reata ($7.3 billion, 2023), HI-Bio ($1.15 billion upfront, 2024) and Apellis (about $5.6 billion, 2026), which together move Biogen into rare disease, immunology, nephrology and ophthalmology.